Received Feb 1, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Cold sores; This non-serious case was reported by a consumer via call center representative and described the occurrence of cold sores in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included valaciclovir hydrochloride (Valtrex). On an unknown date, the patient received Shingrix. On an unknown date, 1 day after receiving Shingrix, the patient experienced cold sores (Verbatim: Cold sores). The outcome of the cold sores was resolved. It was unknown if the reporter considered the cold sores to be related to Shingrix. It was unknown if the company considered the cold sores to be related to Shingrix. Additional Information: GSK Receipt Date: 27-JAN-2026 The patient self-reported this case for herself. The patient stated that she had an outbreak of cold sores the day after receiving a dose of Shingrix. The consumer stated that she was taking Valtrex at the time of vaccination. Consumer stated she continued taking Valtrex and the cold sores resolved. The batch number was not provided, and we are unable to contact the reporter.
VALTREX